Find more items about these cancer types:
Novel Prostate Cancer Drug
(00:03:56) Elsevier Global Medical News, 2009 Feb 28, P Wendling
Dr. Howard Scher is Chief of the Genitourinary Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center in New York.
In a phase I/II trial presented in poster form at ASCO GU, MDV3100, a novel oral androgen receptor antagonist, elicited responses not only in prostate cancer patients who were chemotherapy naïve but also in those who had not responded to chemotherapy previously. According to Dr. Scher, one of the trial investigators, MDV3100 specifically targets overexpression of androgen receptors, an alteration seen in molecularly characterized androgen-resistant prostate cancers, but does not exhibit the stimulatory effects of current antiandrogens.
See related videos to:
ASCO GU 2009
Related Links:
News Article: Novel Agents Take Aim at Castration-Resistant Prostate Cancer »
Subscribe Now »
